BRPI0808421A2 - Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula. - Google Patents

Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula.

Info

Publication number: BRPI0808421A2
Authority: BR; Brazil
Prior art keywords: cell; inducing; cytotoxic; exosome; vaccine
Prior art date: 2007-02-21

Application number

Other languages

English (en)

Inventor

Ryuji Ohsawa

Takuya Tsunoda

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-21

Filing date

2008-02-21

Publication date

2017-08-29

2008-02-21 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2008-02-21 Priority to BR122020021065-6A priority Critical patent/BR122020021065B1/pt

2017-08-29 Publication of BRPI0808421A2 publication Critical patent/BRPI0808421A2/pt

2021-10-05 Publication of BRPI0808421B1 publication Critical patent/BRPI0808421B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/422—Ephrin Receptors [Eph]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/4229—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Dispersion Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)

BRPI0808421-1A 2007-02-21 2008-02-21 Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula BRPI0808421B1 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122020021065-6A BR122020021065B1 (pt)	2007-02-21	2008-02-21	Composição farmacêutica e vacina à base de peptídeos para antígenos associados a tumores expressando câncer, exossomo, método in vitro para induzir células apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica e uso de um peptídeo

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US90294907P	2007-02-21	2007-02-21
US60/902,949		2007-02-21
PCT/JP2008/000290 WO2008102557A1 (en)	2007-02-21	2008-02-21	Peptide vaccines for cancers expressing tumor-associated antigens

Publications (2)

Publication Number	Publication Date
BRPI0808421A2 true BRPI0808421A2 (pt)	2017-08-29
BRPI0808421B1 BRPI0808421B1 (pt)	2021-10-05

Family

ID=39709837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0808421-1A BRPI0808421B1 (pt)	2007-02-21	2008-02-21	Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula

Country Status (27)

Country	Link
EP (20)	EP2570429A3 (pt)
JP (6)	JP5239103B2 (pt)
KR (8)	KR20160045939A (pt)
CN (4)	CN102863514B (pt)
AR (1)	AR068302A1 (pt)
AU (1)	AU2008218463B2 (pt)
BR (1)	BRPI0808421B1 (pt)
CA (3)	CA2678755C (pt)
CO (1)	CO6190536A2 (pt)
CY (2)	CY1114590T1 (pt)
DK (3)	DK2476694T3 (pt)
ES (6)	ES2530777T3 (pt)
HR (3)	HRP20131044T1 (pt)
IL (10)	IL200478A (pt)
MX (4)	MX337417B (pt)
MY (2)	MY155029A (pt)
NZ (4)	NZ579768A (pt)
PH (1)	PH12014501642A1 (pt)
PL (3)	PL2476694T3 (pt)
PT (2)	PT2121731E (pt)
RU (1)	RU2464275C2 (pt)
SG (3)	SG179402A1 (pt)
SI (3)	SI2465864T1 (pt)
TW (5)	TWI494319B (pt)
UA (1)	UA100372C2 (pt)
WO (1)	WO2008102557A1 (pt)
ZA (1)	ZA200905881B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4614952B2 (ja)	2003-08-20	2011-01-19	オンコセラピー・サイエンス株式会社	腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
UA100127C2 (ru)	2007-08-20	2012-11-26	Онкотерапи Саенс, Инк.	Пептид cdh3 и лекарственное средство, содержащее его
CA2729403A1 (en)	2008-06-30	2010-01-07	Oncotherapy Science, Inc.	Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TWI543767B (zh) *	2008-08-19	2016-08-01	腫瘤療法科學股份有限公司	Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
TW201008574A (en) *	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
MX2011004176A (es) *	2008-10-22	2011-09-21	Oncotherapy Science Inc	Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
TWI539160B (zh)	2008-12-05	2016-06-21	腫瘤療法科學股份有限公司	Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
KR20110117112A (ko)	2008-12-24	2011-10-26	온코세라피 사이언스 가부시키가이샤	Ｃ１ｏｒｆ５９ 펩티드 및 이를 포함하는 백신
TW201102081A (en)	2009-05-11	2011-01-16	Oncotherapy Science Inc	TTK peptides and vaccines including the same
US8703808B2 (en)	2009-06-23	2014-04-22	Centre National De La Recherche Scientifique	Use of derivatives of indoles for the treatment of cancer
CN102781964B (zh)	2009-12-28	2015-11-25	肿瘤疗法科学股份有限公司	抗cdh3抗体及其用途
EP2547359B1 (en)	2010-03-15	2016-03-09	The Board of Trustees of the University of Illionis	Inhibitors of beta integrin-g protein alpha subunit binding interactions
TWI538685B (zh)	2010-04-02	2016-06-21	腫瘤療法科學股份有限公司	Ｅｃｔ２胜肽及含此胜肽之疫苗
TWI618541B (zh) *	2010-12-02	2018-03-21	腫瘤療法科學股份有限公司	Ｔｏｍｍ３４胜肽與含此胜肽之疫苗
EP3603678A3 (en) *	2011-12-14	2020-07-29	The Board of Regents of the University of Texas System	Collateral gene inactivation biomarkers and targets for cancer therapy
KR20140138900A (ko)	2012-03-09	2014-12-04	온코세라피 사이언스 가부시키가이샤	펩티드를 포함한 의약 조성물
EP2872531A4 (en) *	2012-07-10	2016-04-06	Oncotherapy Science Inc	LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
WO2014010231A1 (en)	2012-07-10	2014-01-16	Oncotherapy Science, Inc.	Kif20a epitope peptides for th1 cells and vaccines containing the same
US9683016B2 (en)	2012-08-31	2017-06-20	Genestem Co., Ltd.	PSF1-derived peptide
JP6283861B2 (ja)	2012-09-11	2018-02-28	オンコセラピー・サイエンス株式会社	Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
WO2014141652A1 (en) *	2013-03-11	2014-09-18	Oncotherapy Science, Inc.	Smyd3 peptides and vaccines containing the same
TWI658049B (zh) *	2013-03-12	2019-05-01	腫瘤療法科學股份有限公司	Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR20160029127A (ko) *	2013-07-12	2016-03-14	다이니뽄 스미토모 세이야쿠 가부시키가이샤	종양 항원 펩티드
JP2015227292A (ja) *	2014-05-30	2015-12-17	国立大学法人高知大学	膵がん細胞浸潤転移抑制ワクチン
MX2016017393A (es)	2014-07-01	2017-09-05	Pfizer	Diacuerpos heterodimericos biespecificos y sus usos.
US10576097B2 (en) *	2014-08-04	2020-03-03	Oncotherapy Science, Inc.	URLC10-derived peptide and vaccine containing same
GB201507719D0 (en) *	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) *	2015-06-05	2018-11-02	复旦大学附属肿瘤医院	一组用于评估肺癌预后的基因及其应用
SG11201808196UA (en) *	2016-03-31	2018-10-30	Neon Therapeutics Inc	Neoantigens and methods of their use
WO2018090257A1 (zh) *	2016-11-16	2018-05-24	深圳华大基因研究院	多肽及其应用
CN110191703B (zh)	2017-01-25	2022-04-08	奥塞免疫疗法公司	用于肽递送的稳定乳液的制造方法
WO2018183447A1 (en) *	2017-03-28	2018-10-04	Zhenglun Zhu	Methods of treating neoplastic diseases
WO2019031938A2 (ko) *	2017-08-10	2019-02-14	주식회사 굳티셀	암 치료를 위한 t 세포의 활성화 방법
SG11202007750PA (en) *	2018-02-15	2020-09-29	National Univ Corporation Asahikawa Medical Univ	Cancer antigen peptide
KR102335916B1 (ko) *	2019-04-22	2021-12-08	한국과학기술연구원	인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102322832B1 (ko) *	2019-04-22	2021-11-12	한국과학기술연구원	인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113117055A (zh) *	2019-12-31	2021-07-16	上海细胞治疗集团有限公司	一种特异性结合hla-a24分型的多肽组合物及应用
CN117143206B (zh) *	2023-08-03	2024-09-03	华南农业大学	Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
NZ217727A (en) *	1985-10-03	1990-05-28	Genentech Inc	Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
IL103928A0 (en) *	1991-12-11	1993-04-04	American Home Prod	Expression of specific immunogens using viral antigens
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en)	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
EP0756627A1 (en) *	1994-04-15	1997-02-05	Amgen Inc.	Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5736524A (en)	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
US5922687A (en)	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en)	1995-08-03	2006-03-08	Rijksuniversiteit te Leiden	Cell derived antigen presenting vesicles
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja)	1996-07-26	2000-12-05	スローン―ケッタリングインスティチュートフォーキャンサーリサーチ	遺伝子的免疫化のための方法と試薬
AU6795898A (en) *	1997-04-04	1998-10-30	Board Of Regents, The University Of Texas System	Proteins and compositions for modulating mitosis
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1627886A1 (en) *	1997-10-07	2006-02-22	Ono Pharmaceutical Co., Ltd.	Polypeptide, cDNA encoding the same, and use of them
US20070014787A1 (en) *	1998-07-15	2007-01-18	Human Genome Sciences, Inc.	71 human secreted proteins
WO2001029221A2 (en) *	1999-10-20	2001-04-26	Zymogenetics, Inc.	Proteins and polynucleotides encoding them
US6682902B2 (en) *	1999-12-16	2004-01-27	Schering Aktiengesellschaft	DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) *	2000-01-31	2003-01-16	Rosen Craig A.	Nucleic acids, proteins, and antibodies
CN1469926A (zh) *	2000-03-29	2004-01-21	科里克萨有限公司	治疗和诊断肺癌的组合物和方法
WO2002008765A2 (en) *	2000-07-26	2002-01-31	Stanford University	Basal cell markers in breast cancer and uses thereof
US6830885B1 (en) *	2000-08-18	2004-12-14	Phenogene Therapeutiques Inc.	Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) *	2000-10-10	2009-03-05	Hildebrand William H	Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) *	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) *	2001-01-04	2008-07-09	北京迪威华宇生物技术有限公司	预防和治疗人前列腺癌的重组蛋白疫苗
US20040236091A1 (en) *	2001-03-28	2004-11-25	Chicz Roman M.	Translational profiling
CA2444691A1 (en)	2001-04-18	2002-10-31	Protein Design Labs, Inc.	Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
MXPA03011979A (es) *	2001-06-18	2005-04-08	Eos Biotechnology Inc	Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario.
US20030124579A1 (en) *	2001-09-05	2003-07-03	Eos Biotechnology, Inc.	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2003080640A1 (en) *	2002-03-07	2003-10-02	Ludwig Institute For Cancer Research	Lymphatic and blood endothelial cell genes
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) *	2002-04-04	2007-01-18	Rosen Craig A	Human secreted proteins
CA2500687A1 (en) *	2002-10-02	2004-04-15	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20040224408A1 (en) *	2002-12-10	2004-11-11	Jean-Philippe Girard	THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
EP1572118A4 (en) *	2002-12-20	2010-07-14	Millennium Pharm Inc	METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
TWI324608B (en) *	2003-02-28	2010-05-11	Oncotherapy Science Inc	Genes and polypeptides relating to human colorectal cancers
EP1651775A2 (en) *	2003-06-18	2006-05-03	Arcturus Bioscience, Inc.	Breast cancer survival and recurrence
WO2005019258A2 (en) *	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
JP4614952B2 (ja) *	2003-08-20	2011-01-19	オンコセラピー・サイエンス株式会社	腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
EP1730279A2 (en) *	2004-02-27	2006-12-13	Oncotherapy Science, Inc.	Epha4 as therapeutic target of prc and pdaca
EP2495324B1 (en) *	2004-04-09	2015-03-04	Genecare Research Institute Co., Ltd	Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
CA2566506A1 (en) *	2004-06-01	2005-12-15	Innogenetics N.V.	Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2006031221A1 (en)	2004-09-13	2006-03-23	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Compositions comprising t cell receptors and methods of use thereof
CN100381460C (zh) *	2004-11-30	2008-04-16	北京市肿瘤防治研究所	Her-2模拟抗原表位及含有该表位的肽
CA2598889A1 (en) *	2005-02-24	2006-08-31	Cemines, Inc.	Compositions and methods for classifying biological samples
DK2325306T3 (en) *	2005-02-25	2014-03-03	Oncotherapy Science Inc	Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
CN100348614C (zh) *	2005-06-03	2007-11-14	北京大学	一种肝癌－睾丸特异性抗原蛋白质和抗原肽
JP5299942B2 (ja) *	2005-08-09	2013-09-25	オンコセラピー・サイエンス株式会社	ＨＬＡ−Ａ２陽性者用ｇｌｙｐｉｃａｎ−３（ＧＰＣ３）由来癌拒絶抗原ペプチド及びこれを含む医薬
WO2007018047A1 (ja) *	2005-08-09	2007-02-15	Kurume University	Hla-a24分子結合性扁平上皮癌抗原由来ペプチド
CN101287831B (zh)	2005-09-13	2013-05-15	国立大学法人三重大学	T细胞受体和编码该受体的核酸
WO2007064743A2 (en) *	2005-11-30	2007-06-07	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP2343551B1 (en) *	2006-04-10	2014-05-28	Genentech, Inc.	Dishevelled PDZ modulators
RU2451521C2 (ru) *	2006-06-16	2012-05-27	Онкотерапи Сайенс, Инк.	Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
US20090081659A1 (en) *	2007-03-07	2009-03-26	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) *	2007-04-19	2009-03-11	Peter Hornbeck	Tyrosine phosphorylation sites and antibodies specific for them
UA100127C2 (ru) *	2007-08-20	2012-11-26	Онкотерапи Саенс, Инк.	Пептид cdh3 и лекарственное средство, содержащее его
EP2080812A1 (en) *	2008-01-18	2009-07-22	Transmedi SA	Compositions and methods of detecting post-stop peptides
TWI543767B (zh) *	2008-08-19	2016-08-01	腫瘤療法科學股份有限公司	Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
CA2775978A1 (en) *	2009-09-29	2011-04-07	Protagen Ag	Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof

2008
- 2008-02-18 TW TW103114624A patent/TWI494319B/zh not_active IP Right Cessation
- 2008-02-18 TW TW097105594A patent/TWI438207B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103107156A patent/TWI610939B/zh active
- 2008-02-18 TW TW104120673A patent/TWI596109B/zh not_active IP Right Cessation
- 2008-02-18 TW TW105108412A patent/TWI615403B/zh not_active IP Right Cessation
- 2008-02-21 NZ NZ579768A patent/NZ579768A/en not_active IP Right Cessation
- 2008-02-21 EP EP12175482.4A patent/EP2570429A3/en not_active Withdrawn
- 2008-02-21 ES ES12151717T patent/ES2530777T3/es active Active
- 2008-02-21 SG SG2012012126A patent/SG179402A1/en unknown
- 2008-02-21 EP EP12175487.3A patent/EP2573110A3/en not_active Withdrawn
- 2008-02-21 WO PCT/JP2008/000290 patent/WO2008102557A1/en not_active Ceased
- 2008-02-21 PL PL12151717T patent/PL2476694T3/pl unknown
- 2008-02-21 MX MX2013009906A patent/MX337417B/es unknown
- 2008-02-21 ES ES08710443T patent/ES2435194T3/es active Active
- 2008-02-21 ES ES12151722.1T patent/ES2540893T3/es active Active
- 2008-02-21 NZ NZ591704A patent/NZ591704A/xx not_active IP Right Cessation
- 2008-02-21 EP EP12151705.6A patent/EP2476692B1/en not_active Not-in-force
- 2008-02-21 EP EP12175483.2A patent/EP2570430A3/en not_active Withdrawn
- 2008-02-21 PT PT87104436T patent/PT2121731E/pt unknown
- 2008-02-21 HR HRP20131044AT patent/HRP20131044T1/hr unknown
- 2008-02-21 UA UAA200909469A patent/UA100372C2/ru unknown
- 2008-02-21 EP EP12151714.8A patent/EP2476693B1/en active Active
- 2008-02-21 SI SI200831332T patent/SI2465864T1/sl unknown
- 2008-02-21 SG SG10201506589WA patent/SG10201506589WA/en unknown
- 2008-02-21 EP EP12175490.7A patent/EP2574623A3/en not_active Withdrawn
- 2008-02-21 CN CN201210352621.7A patent/CN102863514B/zh active Active
- 2008-02-21 PL PL08710443T patent/PL2121731T3/pl unknown
- 2008-02-21 BR BRPI0808421-1A patent/BRPI0808421B1/pt not_active IP Right Cessation
- 2008-02-21 DK DK12151717.1T patent/DK2476694T3/en active
- 2008-02-21 MX MX2009009022A patent/MX2009009022A/es active IP Right Grant
- 2008-02-21 EP EP12175481.6A patent/EP2570428A3/en not_active Withdrawn
- 2008-02-21 KR KR1020167010159A patent/KR20160045939A/ko not_active Withdrawn
- 2008-02-21 MY MYPI20093446A patent/MY155029A/en unknown
- 2008-02-21 EP EP12175488.1A patent/EP2583976A3/en not_active Withdrawn
- 2008-02-21 EP EP12151723A patent/EP2476695A3/en not_active Withdrawn
- 2008-02-21 DK DK12151711.4T patent/DK2465864T3/en active
- 2008-02-21 SG SG10201909675Q patent/SG10201909675QA/en unknown
- 2008-02-21 EP EP12151719.7A patent/EP2465865B1/en not_active Not-in-force
- 2008-02-21 DK DK08710443.6T patent/DK2121731T3/da active
- 2008-02-21 KR KR1020157013656A patent/KR101644871B1/ko not_active Expired - Fee Related
- 2008-02-21 CA CA2678755A patent/CA2678755C/en active Active
- 2008-02-21 KR KR1020157026286A patent/KR20150116463A/ko not_active Abandoned
- 2008-02-21 KR KR1020147026715A patent/KR101540000B1/ko not_active Expired - Fee Related
- 2008-02-21 CN CN201310183458.0A patent/CN103351423B/zh active Active
- 2008-02-21 KR KR1020137004417A patent/KR101511140B1/ko active Active
- 2008-02-21 SI SI200831368T patent/SI2476694T1/sl unknown
- 2008-02-21 NZ NZ602122A patent/NZ602122A/en not_active IP Right Cessation
- 2008-02-21 CN CN201410449753.0A patent/CN104292299B/zh active Active
- 2008-02-21 EP EP12175478A patent/EP2565203A1/en not_active Withdrawn
- 2008-02-21 CN CN200880012937.3A patent/CN101663315B/zh active Active
- 2008-02-21 PT PT121517114T patent/PT2465864E/pt unknown
- 2008-02-21 KR KR1020147026728A patent/KR101543623B1/ko not_active Expired - Fee Related
- 2008-02-21 SI SI200831053T patent/SI2121731T1/sl unknown
- 2008-02-21 MX MX2013009905A patent/MX337456B/es unknown
- 2008-02-21 KR KR1020157002221A patent/KR101644877B1/ko not_active Expired - Fee Related
- 2008-02-21 EP EP12175484.0A patent/EP2594581A3/en not_active Withdrawn
- 2008-02-21 EP EP12151722.1A patent/EP2465867B1/en active Active
- 2008-02-21 PL PL12151711T patent/PL2465864T3/pl unknown
- 2008-02-21 MX MX2016002567A patent/MX359680B/es unknown
- 2008-02-21 EP EP08710443.6A patent/EP2121731B1/en active Active
- 2008-02-21 CA CA2992074A patent/CA2992074C/en active Active
- 2008-02-21 EP EP12175479.0A patent/EP2573109A3/en not_active Withdrawn
- 2008-02-21 EP EP12151711.4A patent/EP2465864B1/en not_active Not-in-force
- 2008-02-21 KR KR1020097019583A patent/KR101511134B1/ko not_active Expired - Fee Related
- 2008-02-21 AR ARP080100718A patent/AR068302A1/es unknown
- 2008-02-21 EP EP12151717.1A patent/EP2476694B1/en active Active
- 2008-02-21 EP EP12175489.9A patent/EP2594582A3/en not_active Withdrawn
- 2008-02-21 MY MYPI2012004306A patent/MY173379A/en unknown
- 2008-02-21 ES ES12151711.4T patent/ES2527397T3/es active Active
- 2008-02-21 RU RU2009135020/10A patent/RU2464275C2/ru active
- 2008-02-21 NZ NZ602119A patent/NZ602119A/en not_active IP Right Cessation
- 2008-02-21 CA CA2919248A patent/CA2919248A1/en not_active Abandoned
- 2008-02-21 EP EP12175480.8A patent/EP2567971A3/en not_active Withdrawn
- 2008-02-21 ES ES12151705.6T patent/ES2541863T3/es active Active
- 2008-02-21 ES ES12151714.8T patent/ES2532708T3/es active Active
- 2008-02-21 AU AU2008218463A patent/AU2008218463B2/en not_active Ceased
- 2008-02-21 JP JP2009534784A patent/JP5239103B2/ja active Active
- 2008-02-21 EP EP12151720A patent/EP2465866A3/en not_active Withdrawn
2009
- 2009-08-18 IL IL200478A patent/IL200478A/en active IP Right Grant
- 2009-08-25 ZA ZA200905881A patent/ZA200905881B/xx unknown
- 2009-09-21 CO CO09102283A patent/CO6190536A2/es not_active Application Discontinuation
2010
- 2010-02-02 JP JP2010021234A patent/JP5239104B2/ja active Active
2012
- 2012-04-04 IL IL219046A patent/IL219046A/en not_active IP Right Cessation
- 2012-04-04 IL IL219047A patent/IL219047A0/en unknown
- 2012-04-04 IL IL219045A patent/IL219045A0/en unknown
- 2012-04-04 IL IL219048A patent/IL219048A/en not_active IP Right Cessation
- 2012-04-04 IL IL219043A patent/IL219043A/en not_active IP Right Cessation
- 2012-04-04 IL IL219042A patent/IL219042A/en not_active IP Right Cessation
- 2012-04-04 IL IL219044A patent/IL219044A/en active IP Right Grant
- 2012-04-04 IL IL219041A patent/IL219041A/en not_active IP Right Cessation
- 2012-04-04 IL IL219040A patent/IL219040A/en active IP Right Grant
- 2012-11-29 JP JP2012260412A patent/JP5614761B2/ja active Active
- 2012-11-29 JP JP2012260421A patent/JP5608953B2/ja active Active
2013
- 2013-11-08 CY CY20131100994T patent/CY1114590T1/el unknown
2014
- 2014-07-17 PH PH12014501642A patent/PH12014501642A1/en unknown
- 2014-07-24 JP JP2014150295A patent/JP5874158B2/ja not_active Expired - Fee Related
- 2014-12-17 HR HRP20141233AT patent/HRP20141233T1/hr unknown
- 2014-12-18 CY CY20141101067T patent/CY1115841T1/el unknown
2015
- 2015-01-28 HR HRP20150108TT patent/HRP20150108T1/hr unknown
- 2015-12-25 JP JP2015252737A patent/JP2016094459A/ja active Pending

Also Published As

Publication number	Publication date
PT2465864E (pt)	2015-01-14
HK1172345A1 (en)	2013-04-19
WO2008102557A1 (en)	2008-08-28
EP2121731B1 (en)	2013-08-14
EP2476694B1 (en)	2014-11-19
EP2570429A3 (en)	2013-08-28
JP5608953B2 (ja)	2014-10-22
TWI615403B (zh)	2018-02-21
DK2476694T3 (en)	2014-12-08
IL219044A (en)	2014-12-31
EP2465864A3 (en)	2012-10-03
KR101543623B1 (ko)	2015-08-11
SI2465864T1 (sl)	2014-12-31
EP2476694A3 (en)	2013-04-24
EP2573110A2 (en)	2013-03-27
EP2121731A4 (en)	2010-04-21
BRPI0808421B1 (pt)	2021-10-05
EP2476692A2 (en)	2012-07-18
HRP20141233T1 (hr)	2015-02-27
EP2476692B1 (en)	2015-04-15
EP2573110A3 (en)	2013-09-04
EP2594581A3 (en)	2013-08-14
DK2465864T3 (en)	2014-11-24
JP5614761B2 (ja)	2014-10-29
IL219041A0 (en)	2012-05-31
ZA200905881B (en)	2010-05-26
IL219041A (en)	2014-12-31
EP2465865A3 (en)	2013-07-24
RU2464275C2 (ru)	2012-10-20
KR20130023407A (ko)	2013-03-07
MX2009009022A (es)	2010-03-03
AR068302A1 (es)	2009-11-11
IL219045A0 (en)	2012-05-31
CN101663315A (zh)	2010-03-03
KR101644877B1 (ko)	2016-08-03
ES2435194T3 (es)	2013-12-16
EP2476693B1 (en)	2014-12-24
EP2594581A2 (en)	2013-05-22
EP2465867A3 (en)	2012-10-10
EP2583976A2 (en)	2013-04-24
EP2476694A2 (en)	2012-07-18
JP2010209060A (ja)	2010-09-24
HK1172041A1 (en)	2013-04-12
EP2465865B1 (en)	2016-11-02
KR20150018895A (ko)	2015-02-24
MY173379A (en)	2020-01-21
IL219043A (en)	2014-12-31
EP2567971A3 (en)	2013-06-26
JP5239103B2 (ja)	2013-07-17
EP2567971A2 (en)	2013-03-13
AU2008218463A2 (en)	2009-11-26
CN102863514B (zh)	2014-12-10
IL219042A (en)	2016-03-31
IL219040A (en)	2014-12-31
KR20140121489A (ko)	2014-10-15
TW200844111A (en)	2008-11-16
HK1172344A1 (en)	2013-04-19
EP2476695A3 (en)	2012-12-12
CA2919248A1 (en)	2008-08-28
IL219044A0 (en)	2012-05-31
CY1114590T1 (el)	2016-10-05
EP2570430A2 (en)	2013-03-20
JP2014210804A (ja)	2014-11-13
NZ602122A (en)	2014-03-28
IL219047A0 (en)	2012-05-31
HRP20131044T1 (hr)	2013-12-06
JP2013091645A (ja)	2013-05-16
KR20140130507A (ko)	2014-11-10
ES2540893T3 (es)	2015-07-14
EP2574623A3 (en)	2013-07-17
KR101511134B1 (ko)	2015-04-28
IL219046A (en)	2015-02-26
JP5874158B2 (ja)	2016-03-02
TW201422637A (zh)	2014-06-16
IL219048A0 (en)	2012-05-31
PL2121731T3 (pl)	2014-01-31
EP2570429A2 (en)	2013-03-20
EP2465864B1 (en)	2014-10-08
JP2010519176A (ja)	2010-06-03
EP2570428A2 (en)	2013-03-20
JP5239104B2 (ja)	2013-07-17
ES2530777T3 (es)	2015-03-05
CA2992074A1 (en)	2008-08-28
EP2476692A3 (en)	2012-12-19
JP2013116895A (ja)	2013-06-13
UA100372C2 (ru)	2012-12-25
HK1172346A1 (en)	2013-04-19
CY1115841T1 (el)	2017-01-25
MX337417B (es)	2016-03-03
IL219043A0 (en)	2012-05-31
EP2465864A2 (en)	2012-06-20
TWI494319B (zh)	2015-08-01
MY155029A (en)	2015-08-28
TW201623325A (zh)	2016-07-01
ES2541863T3 (es)	2015-07-27
CA2678755A1 (en)	2008-08-28
CN102863514A (zh)	2013-01-09
EP2565203A1 (en)	2013-03-06
TW201433574A (zh)	2014-09-01
KR101540000B1 (ko)	2015-07-29
EP2465867B1 (en)	2015-04-01
KR20090121349A (ko)	2009-11-25
CA2678755C (en)	2016-04-26
NZ579768A (en)	2012-03-30
HK1134507A1 (en)	2010-04-30
EP2465867A2 (en)	2012-06-20
NZ602119A (en)	2014-03-28
CN104292299B (zh)	2017-09-29
IL219042A0 (en)	2012-05-31
HRP20150108T1 (hr)	2015-05-08
EP2570428A3 (en)	2013-07-10
IL219046A0 (en)	2012-05-31
SI2476694T1 (sl)	2015-02-27
EP2573109A2 (en)	2013-03-27
HK1172042A1 (en)	2013-04-12
EP2121731A1 (en)	2009-11-25
PH12014501642B1 (en)	2015-12-02
PL2465864T3 (pl)	2015-03-31
EP2476695A2 (en)	2012-07-18
IL200478A0 (en)	2010-04-29
SG10201909675QA (en)	2019-11-28
CO6190536A2 (es)	2010-08-19
RU2009135020A (ru)	2011-03-27
CN103351423B (zh)	2016-09-28
KR20160045939A (ko)	2016-04-27
CN103351423A (zh)	2013-10-16
SG10201506589WA (en)	2015-09-29
PH12014501642A1 (en)	2015-12-02
KR101511140B1 (ko)	2015-04-10
PL2476694T3 (pl)	2015-04-30
EP2476693A3 (en)	2012-10-03
AU2008218463B2 (en)	2013-01-17
TW201538522A (zh)	2015-10-16
KR20150116463A (ko)	2015-10-15
CN104292299A (zh)	2015-01-21
IL219048A (en)	2015-07-30
CN101663315B (zh)	2014-10-15
ES2527397T3 (es)	2015-01-23
SI2121731T1 (sl)	2013-10-30
MX359680B (es)	2018-09-28
TWI438207B (zh)	2014-05-21
EP2594582A3 (en)	2013-08-14
IL219040A0 (en)	2012-05-31
NZ591704A (en)	2012-09-28
EP2465866A3 (en)	2012-10-10
DK2121731T3 (da)	2013-10-21
PT2121731E (pt)	2013-10-24
EP2476693A2 (en)	2012-07-18
HK1172043A1 (en)	2013-04-12
SG179402A1 (en)	2012-04-27
AU2008218463A1 (en)	2008-08-28
EP2583976A3 (en)	2013-10-23
EP2573109A3 (en)	2013-06-19
EP2465865A2 (en)	2012-06-20
KR20150064236A (ko)	2015-06-10
KR101644871B1 (ko)	2016-08-02
JP2016094459A (ja)	2016-05-26
ES2532708T3 (es)	2015-03-31
TWI610939B (zh)	2018-01-11
EP2570430A3 (en)	2013-07-10
TWI596109B (zh)	2017-08-21
EP2594582A2 (en)	2013-05-22
MX337456B (es)	2016-03-03
CA2992074C (en)	2021-01-05
EP2574623A2 (en)	2013-04-03
EP2465866A2 (en)	2012-06-20
IL200478A (en)	2015-11-30

Publication	Publication Date	Title
CL2008001633A1 (es)	2008-12-12	Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
UA100372C2 (ru)	2012-12-25	Выделенный пептид, способный индуцировать цитотоксические т-клетки, и его применение в качестве вакцины
CL2011001536A1 (es)	2011-10-14	Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer.
CL2008001540A1 (es)	2009-05-22	Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
MX2009008926A (es)	2009-09-14	Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2009000483A1 (es)	2010-02-19	Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2012002189A1 (es)	2012-11-23	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
BR112015014969A2 (pt)	2017-07-11	micromatriz para entrega de agente terapêutico e métodos de uso
CL2012002606A1 (es)	2013-10-18	Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2011001215A1 (es)	2011-09-30	Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
CL2008002243A1 (es)	2009-08-21	Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2007002635A1 (es)	2009-10-23	Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
CL2010001483A1 (es)	2011-05-13	Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
CL2007000311A1 (es)	2008-01-25	Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2012000772A1 (es)	2012-08-24	Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
BRPI0810524A2 (pt)	2014-10-21	Derivado de (aza)indol e uso do mesmo para propósitos médicos
CL2008002381A1 (es)	2009-02-13	Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
CL2007003552A1 (es)	2008-07-18	Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
ECSP088752A (es)	2008-10-31	Formulaciones para administración parenteral de compuestos y sus usos

Legal Events

Date	Code	Title	Description
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-06-25	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-05-19	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-08-18	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-03-02	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-04-20	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2021-08-03	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-10-05	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/02/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2023-12-12	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2024-04-02	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2762 DE 12-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.